cilostazol has been researched along with Carotid Arteriopathies, Traumatic in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression." | 7.78 | Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells. ( Matsumura, A; Nakamura, K; Suzuki, K; Takigawa, T; Tsurushima, H; Tsuruta, W, 2012) |
| "These results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression." | 3.78 | Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells. ( Matsumura, A; Nakamura, K; Suzuki, K; Takigawa, T; Tsurushima, H; Tsuruta, W, 2012) |
| " Recent studies have shown that cilostazol, a selective type 3 phosphodiesterase inhibitor, prevents neointimal hyperplasia and in-stent thrombosis in patients with diabetes after coronary angioplasty and stent implantation." | 3.75 | Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. ( Cho, WH; Choi, HS; Hur, SH; Jung, GS; Kim, BW; Kim, HS; Kim, HT; Kim, JG; Kim, MK; Lee, HJ; Lee, IK; Lee, KM; Lee, KU; Lim, JO; Park, KG, 2009) |
| "Cilostazol(CLZ) has been used as a vasodilating anti-platelet drug clinically and demonstrated to inhibit proliferation of smooth muscle cells and effect on endothelial cells." | 1.37 | Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. ( Asahara, T; Ii, M; Itakura, T; Kawabe-Yako, R; Masaaki, I; Masuo, O, 2011) |
| "Cilostazol is a potent antiplatelet agent that inhibits VSMC proliferation." | 1.33 | Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. ( Chang, YC; Kim, CS; Kim, HS; Kim, MJ; Kim, SY; Lee, IK; Lee, KM; Lee, KU; Lee, SL; Park, JY; Park, KG, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, WJ | 1 |
| Chen, YH | 1 |
| Hsu, YJ | 1 |
| Lin, KH | 1 |
| Yeh, YH | 1 |
| Lee, KM | 2 |
| Lee, HJ | 1 |
| Kim, MK | 1 |
| Kim, HS | 2 |
| Jung, GS | 1 |
| Hur, SH | 1 |
| Kim, HT | 1 |
| Cho, WH | 1 |
| Kim, JG | 1 |
| Kim, BW | 1 |
| Lim, JO | 1 |
| Choi, HS | 1 |
| Lee, KU | 2 |
| Park, KG | 2 |
| Lee, IK | 2 |
| Kawabe-Yako, R | 1 |
| Ii, M | 1 |
| Masaaki, I | 1 |
| Masuo, O | 1 |
| Asahara, T | 1 |
| Itakura, T | 1 |
| Takigawa, T | 1 |
| Tsurushima, H | 1 |
| Suzuki, K | 1 |
| Tsuruta, W | 1 |
| Nakamura, K | 1 |
| Matsumura, A | 1 |
| Kim, MJ | 1 |
| Kim, SY | 1 |
| Kim, CS | 1 |
| Lee, SL | 1 |
| Chang, YC | 1 |
| Park, JY | 1 |
5 other studies available for cilostazol and Carotid Arteriopathies, Traumatic
| Article | Year |
|---|---|
MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular smooth muscle cell differentiation.
Topics: 3' Untranslated Regions; Animals; Binding Sites; Calcium-Binding Proteins; Calponins; Cardiovascular | 2018 |
Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.
Topics: Angioplasty, Balloon; Angiotensin II; Animals; Binding Sites; Blood Glucose; Carotid Arteries; Carot | 2009 |
Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model.
Topics: Animals; Bone Marrow Cells; Carotid Artery Injuries; Catheterization; Cilostazol; Endothelial Cells; | 2011 |
Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells.
Topics: Angioplasty, Balloon; Animals; Anti-Inflammatory Agents; Carotid Arteries; Carotid Artery Injuries; | 2012 |
Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Carotid Artery Injuries; Catheterization; Cell Cycl | 2005 |